New drug ARGX-213 passes first safety check in healthy people
NCT ID NCT06968338
First seen Nov 21, 2025 · Last updated May 16, 2026 · Updated 18 times
Summary
This early-stage study tested the safety of a new drug called ARGX-213 in 88 healthy adults. Researchers also measured how the drug moves through the body and affects immune markers. The study is complete and helps lay the groundwork for future research, but offers no direct treatment benefit to participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Altasciences
Montreal, QC H3P 3P1, Canada
Conditions
Explore the condition pages connected to this study.